Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials. 2020

Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang, 330006, China.

BACKGROUND For patients with hormone receptor (HR)-positive advanced breast cancer, whether the combination of anastrozole and fulvestrant is more effective than anastrozole alone is controversial. Our meta-analysis aimed to compare the efficacy and safety of the two therapies. METHODS We retrieved relevant studies in Embase, the Cochrane Library, Ovid MEDLINE, PubMed, ScienceDirect, Web of Science, Scopus, and Google Scholar. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The secondary outcomes were the disease control rate (DCR), the objective response rate (ORR), and adverse events (AEs). RESULTS Five articles based on 4 randomized controlled trials containing 2146 patients were identified in our meta-analysis. The combination group had better efficacy in the endpoints of OS (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.74-0.99, p = 0.03) and PFS (HR 0.87; 95% CI 0.77-0.97, p = 0.02). Regarding the ORR, DCR, total AEs and grade 3-5 AEs, we found no difference between the two treatments. The combination group showed a clearly higher rate of treatment discontinuations (95% CI 1.05-3.60, p = 0.03) and AEs leading to death (95% CI 1.12-9.11, p = 0.03). The subgroup analysis of AEs showed an increased incidence of extremity or muscle pain, hematologic effects, gastrointestinal disorders, and hot flashes in the combination group. CONCLUSIONS For HR-positive advanced breast cancer patients, the combination of anastrozole and fulvestrant appears to be superior to anastrozole alone in extending PFS and OS, despite relatively serious AEs.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077267 Fulvestrant An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer. 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol,Faslodex,ICI 182,780,ICI 182780,ICI-182780,ZM 182780,ZM-182780,ICI182780,ZM182780
D000077384 Anastrozole A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women. 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile),Anastrazole,Arimidex,ICI D1033,ZD-1033,ZD1033,Zeneca ZD 1033,ZD 1033
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical

Related Publications

Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
May 2017, Breast cancer (Tokyo, Japan),
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
November 2019, JAMA oncology,
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
May 2020, Breast cancer (Tokyo, Japan),
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
January 2018, OncoTargets and therapy,
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
January 2014, Asian Pacific journal of cancer prevention : APJCP,
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
April 2013, Breast cancer research and treatment,
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
November 2017, European journal of cancer care,
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
January 2018, PloS one,
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
August 2020, BMJ open,
Meng Li, and Yiting Xiong, and Chen Liao, and Yunyan He, and Sijia Duan, and Fengming Yi, and Yiping Wei, and Wenxiong Zhang
May 2019, The Lancet. Oncology,
Copied contents to your clipboard!